BNY

Bank of New York Mellon Corp

Fundamental data last updated:July 12, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Financial Services

industry

Investment - Banking & Investment Services

Exchange

NYSE

County of HQ

US

Next Earnings Date

07/15/2026

Business Summary

The Bank of New York Mellon Corp. is a holding company, which engages in the provision of financial services. It operates through the following segments: Securities Services, Market and Wealth Services, Investment and Wealth Management, and Other. The Securities Services segment includes the Asset Servicing business, which provides global custody, fund accounting, integrated middle-office solutions, transfer agency and data, and analytics solutions. The Market and Wealth Services segment consists of the Pershing, Clearance and Collateral Management, and Treasury Services businesses. The Investment and Wealth Management segment is involved in services to institutional and retail investors, as well as investment management, wealth, and estate planning. The Other segment refers to the leasing portfolio, corporate treasury activities, derivatives, and other trading activity. The company was founded by Alexander Hamilton on June 9, 1784 and is headquartered in New York, NY.

 


Analyze BNY on TradingView

VALUATION

P/E

17.62

Market Cap ($M USD)

$104.27B

Forward P/E

N/A

PEG

N/A

PRICE TO SALES

2.56

PRICE TO BOOK

2.34

EV / EBITDA

-3.15

5-Year Average P/E

Free Cash Flow Yield

1.40%

DCF Value

$430.18

Graham Number

$112.13

Price to FCF

71.67

EV to FCF

-20.28

Earnings Yield

5.68%

FCF Yield

1.40%

DIVIDEND

Yield

1.40%

Annual Payout

$2.12

Payout Ratio

28.60%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

$8.62

Next Year EPS Growth Estimate

$0.00

Next Year Revenue Growth Estimate

$2.45T

Return on Equity (ROE)

13.48%

FREE CASH FLOW

Operating Margin

18.58%

Debt-to-Equity

0.76

Piotroski F-Score

6

Altman Z-Score

-0.08

Return on Invested Capital (ROIC)

8.18%

Current Ratio

0.57

Quick Ratio

0.57

Net Debt to EBITDA

-14.27

Interest Coverage

0.37

Gross Profit margin

50.52%

FCF PER SHARE

$2.11

REVENUE PER SHARE

$58.82

Analyze BNY on TradingView

Gainseekers Quantitative Analysis

Summary

GSK’s valuation presents a striking disconnect between market perception and intrinsic worth. Recent pricing indicated it traded significantly below its DCF value, suggesting a potential mispricing. The Forward P/E of 8.46 and a robust Earnings Yield of 7.85% imply undervaluation, especially when juxtaposed with a healthy ROIC of 18.11%. However, the Altman Z-score of 1.63 raises concerns about financial stability, hinting at potential distress. This mixed bag of metrics paints a complex picture of opportunity and caution.

AI Exposure / Tech Reliance

Operating in the healthcare sector, GSK is well-positioned to leverage AI advancements for drug discovery and personalized medicine. The industry’s inherent need for innovation aligns with tech-driven efficiencies. GSK's ability to integrate AI could enhance its R&D capabilities, driving future growth.

The Bull Case

For the discerning GARP investor, GSK offers compelling reasons to buy. With a Piotroski F-Score of 7, the company demonstrates strong financial health and operational efficiency. Its ROIC of 18.11% underscores effective capital allocation, while a solid operating margin of 22.34% reflects pricing power. The FCF Yield, though modest, indicates potential for cash generation, making GSK an attractive prospect for those seeking value with growth potential.

The Bear Case

Despite its strengths, GSK faces significant structural risks. The Price/Book ratio of 4.16 and Price/Sales of 2.25 suggest a premium valuation, potentially limiting upside. A Current Ratio of 0.79 and Quick Ratio of 0.52 highlight liquidity concerns, raising red flags about short-term financial flexibility. Additionally, trading near its 52-week high could indicate technical overextension, warranting caution.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Hold

Average Analyst Price Target

$146.63

Institutional Ownership %

1-Year Beta

1.06

Insider Buying % (6 Mo)

Distance to 52-Week High

2.08%

Distance to 52-Week Low

38.54%

EARNINGS SURPRISE %

14.80%

50-DAY SMA

$140.87

200-DAY SMA

$122.58

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.